tbuckley/cabot-search huggingface dataset:
AB0509 Comparative effectiveness of tocilizumab (TCZ) and rituximab (RTM) using different disease activity indices (DAS 28, SDAI and CDAI) in patients with rheumatoid arthritis (RA)
Authors: A.S. Avdeeva, E.N. Alexandrova, E.Y. Panasyuk, G.V. Lukina, E.L. Nasonov
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody (TCZ) and chimeric monoclonal antibody against CD 20 positive B cells (RTM) are effective and safe preparations for the treatment of RA. Taking into account the different mechanisms of action, time of coming effect, influence on a acute -phase reactants, it is interesting to compare the effectiveness of treatment TCZ and RTM using different composite disease activity indices (DAS 28, SDAI and CDAI) and the new criteria remission ACR/EULAR 2011. <h3>Methods</h3> The study included 76 RA patients (pts), divided into two groups. The first group included 42 pts with RA (32 women, mean age 50.5, 43-55, mean disease duration 56.5, 23-81 months). All pts received 6 intravenous TCZ infusions (8 mg/kg) every 4 weeks, in combination with DMARDs and glucocorticoids. The second group - 34 pts with RA (31 women, mean age 49, 42-64, mean disease duration 66, 36-132 months) received two intravenous infusions of RTM - 35% at a dose of 500 mg, 65% of the dose of 1000 mg every two weeks in combination with DMARDs and glucocorticoids. 38% of the patients of the second group received previous biologic therapy. Erythrocyte sedimentation rate – ESR (mm/hr) (Westergren method); serum concentrations of CRP (mg/L), IgM RF (IU/ml) (laser nephelometry); antibodies to cyclic citrullinated peptide – anti-CCP2 (U/ml) (electrochemiluminiscent assay) <h3>Results</h3> First group: baseline meanings [Me (interquartile range)] DAS 28 were (5,87-7,04), SDAI 45,0 (36,2-57,0) and CDAI 41,5 (32,0-53,0). On the 24-th week: DAS 28 2,11 (1,29-2,77), SDAI 4,4 (2,0-8,8) and CDAI 3,6 (1,4-7,6). Second group: baseline meanings [Me (interquartile range)] DAS28 were (5,52-6,81), SDAI 34,3 (23,8-45,9) and CDAI 31,3 (21,8 - 38.5). On the 24-th week: DAS 28 3,53 (2,61-4,00), SDAI 7,5 (4,9-11,7) and CDAI 5,5 (3,5-9,5). In the first and the second group pts on the 24-th week of therapy remission was achieved on DAS 28 in 71% and 23.5%, SDAI in 31% and 14.7%, CDAI in 33% and 17.6% respectively. Low disease activity - DAS 28 12% in the group TCZ and 20.5% in the group of RTM, the SDAI- 50% and 55.8%, CDAI- 47.6% and 58.8%. Among biologic-naïve pts second group DAS 28/SDAI/CDAI remission achieved more frequently (38%/23.8%/28.6%) than pts who received prior biologic therapy (0) and was comparable to frequency of remission in pts of the first group (the indices SDAI and CDAI).The remission on new criteria of ACR/EULAR 2011 the first group pts was 24%, second group - 11.8% <h3>Conclusions</h3> The DAS 28 remission is higher during therapy TCZ, which is associated with a strong effect on the level of acute-phase reactants, while the SDAI and CDAI remission is almost comparable to the therapy TCZ and RTM, amongbiologic-naïve patients <h3>Disclosure of Interest</h3> None Declared
Impact of the number of involved lymph nodes and nodal ratio on survival in esophageal cancer
Authors: Y. Chen, T. Schultheiss, J. Y. Wong
Journal: Journal of Clinical Oncology (2008)

4548 Background: A large data set of patients with esophageal cancer was analyzed to determine the impact of the number of involved nodes and nodal ratio, positive/excised nodes, on overall survival. Methods: Cases of esophageal cancer with data available on the number of nodes examined were identified and extracted from the National Oncology Database, a proprietary database owned by IMPAC Medical System, Inc (Sunneyvale, CA), that consists of merged tumor registries from more than 130 hospitals across the US. In addition to the number of involved nodes and nodal ratio, variables related to overall survival including age, race, sex, tumor stage, grade, chemotherapy, esophagectomy, radiation dose and tumor size were studied by multivariate analysis using Cox proportional hazards method. Patients with 0, exactly 1 or exactly 2 positive nodes were separately studied to determine the impact of number of lymph node dissected on survival. Patients with adequate or inadequate nodal dissection were identified and studied to determine the impact of number of positive nodes and nodal ratio on survival. Results: 3,278 cases were identified that had adequate nodal information. Increasing number of involved nodes predicted poorer outcome. Results from studying patients with exactly 0, 1, or 2 positive nodes showed that survival improved as the number of nodes examined increased, up to approximately 12. Seven hundred and five patients with 12 or more nodes examined were identified and studied. Three-tier nodal grouping with increasing risk could be identified, 0, 1–3, and ≥4 positive nodes (table). Nodal ratio is found to be a powerful indicator as well, even for patients with inadequate nodal dissection. Conclusions: Increasing number of positive nodes indicates poorer survival. Adequate nodal dissection is necessary for a better outcome. It is recommended at lease 12 nodes are necessary to assess the extent of nodal disease. Three-tier nodal grouping is suggested for the next version of AJCC staging system for esophageal cancer. No. of LNs dissected Positive nodes Hazard ratio P ≥12 0 1 <10-5 1–3 1.97 ≥4 4.18 <12 0 1 <10- 5 1–3 1.56 ≥4 2.16 No significant financial relationships to disclose.
GENETIC DETERMINATION OF COLLAGEN SYNTHESIS AND DEGRADATION IN PATIENTS WITH FLOPPY MITRAL VALVE/MITRAL VALVE PROLAPSE
Authors: Sarah Lima, Efstatrios K. Theofilogiannakos, Konstantinos Boudoulas, Mohamed H. Shahin, Issam S. Hamadeh, Taimour Y. Langaee, Larissa H. Cavallari, Antonios A. Pitsis, Harisios Boudoulas
Journal: Journal of the American College of Cardiology (2016)
P60 How Often Do Patients with Tuberculosis Require Enhanced Case Management?
Authors: A Gebril, C Bell, M Woodhead
Journal: Thorax (2012)

An enhanced level of case management (ECM) is recommended by NICE for those deemed ‘hard to reach’ and should be provided where risk/needs assessment demonstrates that the patient has clinically and/or socially complex needs. NICE recommends one TB nurse for every 20 such cases so knowledge of their numbers is integral to workforce planning. <h3>The Aim</h3> of this project was to identify and quantify those qualifying for ECM in an inner city TB cohort. <h3>Methodology</h3> All 170 cases notified with TB in Central Manchester were retrospectively identified from department records for 01/2010 to 12/2010. Data were collected using a standard proforma from clinic letters and TB specialist nurses documentations. Standard case management was defined as per the RCN document ‘Tuberculosis case management and cohort review’. Only 60/170 (35%) were identified as standard management cases in which 7/60 (11%) had other co-morbidities and 4/60 (6%) had a language barrier. 14/60 (23%) were excluded for diverse reasons (e.g. death before diagnosis). <h3>Results</h3> 96/170 (56%) were identified as ECM cases which subdivided according to their requirements into either: Medical needs, which comprised 12.5% (12/96) of cases including patients with dual pathology and recurrent hospital admissions. Nursing needs which comprised 12.5% (12/96) of cases in which majority (8/12) of these did not attend clinics as required and the rest (4/12) had anti-TB treatment side effects demanding more home visits. Both medical as well as nursing needs were present in 75% (72/96). In which 52% were paediatric, 11% had resistant organism, 6% were HIV +ve, 4% of patients declined treatment, 3% were on DOT, 3% had complications due to TB infection and 21% of cases had prolonged treatment due to CNS/bone involvement, interaction with other non TB treatment, immune compromised patients and overlap with others (HIV patients, Drug resistant organism, patients on DOT had prolonged treatment). <h3>Conclusions</h3> The reasons for ECM are many and diverse and often multiple. In our practise more than half of patients could be classified as requiring such management. This has implications for TB nurse manpower planning.
AB0552 Correlation between Change in Esspri Items and Change in Essdai Domains
Authors: S. Nishiyama, K. Ohashi, T. Aita, Y. Yoshinaga, S. Miyawaki
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Novel disease activity indices for primary Sjögren9s syndrome, which are EULAR Sjögren9s syndrome patient reported index (ESSPRI) and EULAR Sjögren9s syndrome disease activity index (ESSDAI) have been recently developed. It is not clear that the relationship between each item of ESSPRI and each domain of ESSDAI. <h3>Objectives</h3> To examine correlation between each item of ESSPRI and each domain of ESSDAI. <h3>Methods</h3> Sixty-five female patients with primary Sjögren9s syndrome who visited our hospital completed ESSPRI and ESSDAI. Forty of them were assessed by these indices more than once at their revisit to our hospital. Average period of time between the assessments was 7.2 months. Multivariate analysis was used to test which domains of ESSDAI correlated with ESSPRI items (dryness, fatigue, and pain). <h3>Results</h3> Mean (SD) of ESSPRI and ESSDAI were 4.6 (2.0) and 3.7 (4.3), respectively. There was no correlation between ESSPRI and ESSDAI (r =0.08) as reported previously<sup>1</sup>, and also no correlation between ΔESSPRI and ΔESSDAI was found (r =0.16). There was no correlation between ESSPRI items and ESSDAI domains. In contrast, Δdryness inversely correlated with Δrenal domain (<i>p</i>=0.015) and Δcutaneous domain (<i>p</i> =0.03), and Δfatigue correlated with Δarticular domain (<i>p</i> =0.037) and Δhematological domain (<i>p</i> =0.009); however, there was no correlation between Δpain and any of ESSDAI domains. <h3>Conclusions</h3> Although ESSPRI items did not associate with ESSDAI domains, change in dryness and fatigue correlated with change in some domains of ESSDAI. This finding suggests that extraglandular worsening and improvement in specific domains may affect change in dryness and fatigue symptoms. <h3>References</h3> Seror R, et al. Arthritis Care Res. 2013;65:1358-1364. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5068
Nodular Lymphoma — Evidence for Origin from Follicular B Lymphocytes
Authors: Elaine S. Jaffe, Ethan M. Shevach, Michael M. Frank, Costan W. Berard, Ira Green
Journal: New England Journal of Medicine (1974)

Abstract To investigate the cellular origin of nodular lymphoma, neoplastic cells from six patients with nodular lymphomas were studied both in cell suspensions and in frozen tissue sections for (1...
Abstract 3459: Radioresistence mechanism of prostate cancer stem cells
Authors: Mun jung Kang, Young Seok Kim, Yong Mee Cho
Journal: Cancer Research (2012)

Abstract BACKGOUND. Radiotherapy induces tumor cell killing mainly by DNA damage and is widely used as one of the main therapeutic modalities for prostate cancer. However, a significant proportion of prostate cancer patients experiences tumor recurrence after radiotherapy and eventually dies of the disease. We previously observed that ionizing radiation (IR) initially damaged prostate cancer stem cells (pCSCs) but levels of CSCs were increased in the recurrent tumors of prostate cancer cell lines and human prostate cancer tissues. METHODS. To define the radioresistance mechanism of pCSCs, we examined expressions of DNA-repair proteins [Ku70, Ku80 and Ataxia telangiectasia and Rad3-related protein kinase (ATR)], cell cycle distribution, and levels of intracellular reactive oxygen species (ROS) in prostaspheres, which is one of pCSC models, and compared to those of total population of a prostate cancer cell line LNCaP. Expressions of DNA-repair proteins were also examined in human prostate cancer tissues harvested before and after radiotherapy. RESTULTS. In non-irradiated cells, the expressions of Ku70 and Ku80 were higher in prostaspheres compared to those of total population. ATR expression was inconspicuous in both cells. After IR with 10 Gy, the expressions of Ku 70, Ku 80, and ATR proteins were increased in both cells with higher levels in prostaspheres than those of total population. Although there was a tendency that prostaspheres belonged to more in G1 phase and less in S phase of cell cycle, it was not statistically significant. Apoptotic cell population and expressions of total and cleaved forms of caspase 3 were not different between prostaspheres and total population. Prostaspheres contained one group of cells that had low levels of ROS. In recurrent human prostate cancer tissue after radiotherapy, expressions of Ku70 and Ku80 were tended to increase. CONCLUSIONS. These results demonstrate that pCSCs contain more DNA-repair proteins and less amount of RCO compared to total population. They suggest that pCSCs have better DNA-repair mechanism and less vulnerability to oxidative damage compared to differentiated cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3459. doi:1538-7445.AM2012-3459
Abstract 3416: Ubiquitous Brms1 expression is critical for mammary carcinoma metastasis suppression via promotion of apoptosis
Authors: Leah M. Cook, Xuemei Cao, Alexander E. Dowell, Andra A. Frost, Renee A. Desmond, Mick D. Edmonds, Robert A. Kesterson, Douglas R. Hurst, Danny R. Welch
Journal: Cancer Research (2012)

Abstract Morbidity and mortality in breast cancer patients are drastically increased when primary tumor cells are able to spread to distant sites and proliferate to become secondary lesions. Effective treatment of metastatic disease has been limited; therefore, increased molecular understanding to identify biomarkers and targets is needed. We have previously shown that breast cancer metastasis suppressor 1 (Brms1) can suppress development of pulmonary metastases when expressed in a variety of cancer types, including metastatic mammary carcinoma. Our lab has developed two transgenic Brms1 mouse models, one which expresses murine Brms1 cDNA specifically in mammary tissue (expression by the mouse mammary tumor virus (MMTV) promoter) and a ubiquitous Brms1 expression model (expression by the chicken beta actin promoter). The goal of this study was to investigate mechanisms of Brms1-mediated metastasis suppression in transgenic mice that express Brms1 using a polyoma middle T (PyMT) oncogene-induced model. Brms1 expression, either ubiquitously or predominantly in the mammary gland, did not significantly alter growth of the primary tumor, confirming earlier studies. When expressed ubiquitously, Brms1 suppressed pulmonary metastasis and promoted tumor cell apoptosis in the lung but not in the mammary gland. However, selective expression of Brms1 in the mammary gland using the MMTV promoter did not significantly block metastasis nor did it promote apoptosis in mammary glands or lungs despite increased expression within primary tumors and the lungs. These results suggest tissue- or cell-type specific expression of Brms1 is a critical determinant for Brms1-mediated metastasis suppression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3416. doi:1538-7445.AM2012-3416
Influenza season 2013/14 has started in Europe with influenza A(H1)pdm09 virus being the most prevalent subtype
Authors: C Adlhoch, E Broberg, J Beauté, R Snacken, E Bancroft, P Zucs, P Penttinen
Journal: Eurosurveillance (2014)

The 2013/14 influenza season has started in Europe. Four countries have reported medium intensity influenza activity, with children under 15 years being the most affected age group. A growing number of countries see increasing rates of influenza-like illness or acute respiratory infection and increasing proportions of specimens positive for influenza A(H1)pdm09 virus. In previous seasons, this subtype was associated with higher reported numbers of severe and fatal cases. Clinicians should offer influenza vaccination to unvaccinated persons belonging to risk groups.
Large retention cyst with chondromatous metaplasia in the esophagus
Authors: S. Tano, K. Tanaka, T. Iguchi, K. Nishikawa, R. Takayama, K. Ninomiya, H. Inoue, M. Katsurahara, N. Horiki, Y. Takei
Journal: Endoscopy (2011)

A 52-year-old man with a 2-year history of diabetes mellitus underwent esophagogastroduodenoscopy (EGD) as part of a medical check-up. He had no symptoms. EGD revealed a semipedunculated polyp, 50 mm long and 20 mm in diameter, in the thoracic esophagus ([Fig. 1 a]). The polyp was covered by normal mucosa with mildly dilated vessels ([Fig. 1 b, c]). Endoscopic ultrasound (EUS) showed multilocular hypoechoic areas within the second layer ([Fig. 2]) and an intact fourth layer in the stalk of the polyp. Double-contrast esophagogram also showed a semipedunculated polyp hanging down from the thoracic esophagus ([Fig. 3]). Although the esophageal polyp was thought likely to be a submucosal cyst of the esophagus, the patient requested treatment of the polyp before symptoms, such as discomfort in the esophagus or dysphagia, developed. The patient understood the risks of endoscopic treatment and provided written informed consent.
Abstract 4870: High-throughput proteomics using stable isotope labelling with amino acids in cell culture (SILAC) reveals potential modulators of androgen-independent prostate cancers
Authors: Punit Saraon, Ihor Batruch, Chris Smith, Atsushi Mizokami, Keith Jarvi, Eleftherios P. Diamandis
Journal: Cancer Research (2011)

Abstract Prostate cancer is the most common malignancy and the second leading cause of cancer related deaths in men. One common treatment is androgen-deprivation therapy, which reduces symptoms in most patients. However, over time patients develop tumours that are androgen-independent and ultimately fatal. The mechanisms that cause this transition remain largely unknown, and as a result, there are no effective treatments against androgen-independent prostate cancer. As a model for androgen-independence, we used the LNCaP cell line which is naturally androgen-dependent grown in androgen depleted conditions for a 6 month period to generate the androgen-independent cell line LNCaP-SF. Preliminary experiments showed that the LNCaP-SF cell line had higher proliferation/viability rates in androgen-depleted conditions, and had increased expression of the androgen receptor protein, a key modulator in prostate cancer progression. Our next goal was to assess to differential global protein expression as well as differential expression of secreted proteins from each of the two cell lines. To identify differentially expressed proteins, we utilized Stable Isotope Labelling with Amino Acids in Cell Culture (SILAC) coupled to mass spectrometry. LNCaP cells were labelled in growth media containing light-Arg/Lys whereas LNCaP-SF was labelled in heavy Arg-Lys media. After proteomic analysis, we were able to quantify 3355 proteins with at least one peptide hit. From these proteins, using stringent criteria, 99 and 82 proteins were found to be up-regulated and down-regulated respectively, in LNCaP-SF cells compared to LNCaP cells. Using various bioinformatics tool, we found that genes involved in fatty acid degradation and ketogenesis as important pathways that with over-expressed in LNCaP-SF cells. We performed qPCR validation of genes involved in each of these pathways and found that LNCaP-SF cells generally had an increase in the expression of many these genes, compared to LNCaP cells. These preliminary results show that genes involved in fatty acid degradation and ketogenesis pathways could serve as potential biomarkers for androgen-independent prostate cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4870. doi:10.1158/1538-7445.AM2011-4870
P593Human vascular pericytes and cardiac progenitor cells combined transplantation for heart repair
Authors: E Avolio, G Mangialardi, F Riu, R Katare, K Mitchell, Z Dang, H Spencer, M Meloni, AP Beltrami, P Madeddu
Journal: Cardiovascular Research (2014)

Purpose: to compare the regenerative potential of Saphenous Vein-derived Pericytes (SVPs) with that of c-Kit-pos Cardiac Progenitor Cells (CPCs) in a mouse model of myocardial infarction (MI), and to investigate if the simultaneus transplantation of the cells produces additive improvements.
Abstract 1697: Gadd45A expression is high in luminal A and her2 human breast cancers, but frequently absent in triple negative breast cancers
Authors: Jennifer S. Tront, Alliric Willis, Yajue Huang, Geoffery Smith, Benjamin Powers, Barbara Hoffman, Dan Liebermann
Journal: Cancer Research (2012)

Abstract Gadd45a is a stress sensor, playing an important role in tumorigenesis. Generation and side by side analysis of breast cancer prone MMTV-myc and MMTV-ras mice highlight a unique role for Gadd45a as either a suppressor or promoter of breast cancer development, employing distinct signaling pathways in response to distinct oncogenic stress stimuli. Thus, it appears that gadd45a can function to either promote or suppress breast tumor development in mice via engagement of different signaling pathways depending on the molecular nature of the activated oncogene. Extending the work to human breast cancer has provided initial, novel data, showing that Gadd45a, which is not expressed in normal breast tissue, is expressed at high levels in less aggressive breast cancers and is low or absent in more aggressive subtypes. Notably, Gadd45a is expressed at very high levels in luminal A and her2 positive breast cancers, but frequently is absent in triple negative breast cancers. Experiments are currently underway to elucidate the functional role of Gadd45a in human breast cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1697. doi:1538-7445.AM2012-1697
Stat Bite: Cigratee ads and Smoking Risk: Coverage in Magazines
Authors: T. Reynolds
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article Stat Bite: Cigratee ads and Smoking Risk: Coverage in Magazines Get access Tom Reynolds Tom Reynolds Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 10, 20 May 1992, Page 749, https://doi.org/10.1093/jnci/84.10.749 Published: 20 May 1992